BIOCON Biocon Q3 FY26 results (Oct–Dec 2025) and concall
Biocon reported a robust Q3 FY26, with group operating revenue growing 9% year-on-year to INR 4,173 crores and core EBITDA up 21% to INR 1,221 crores. This performance was driven by strong growth in Biosimilars and Generics, despite a decline in the CRDMO segment. The company also significantly strengthened its balance sheet by retiring approximately $550-600 million in structured debt, leading to credit rating upgrades and reduced finance costs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 9.2%, net profit down 164.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 +20% | 4,173 +9% |
| EBITDA | 685 | 752 | 1,078 | 766 | 835 +22% | 834 +11% |
| Net profit | 27 | 81 | 459 | 89 | 133 +393% | -52 −164% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
